Modeling Is Not a Drug Approval Pathway: Why Merck Flunked Keytruda’s TNBC Advisory Panel

 
• By Sarah Karlin-Smith
photo illustration/shutterstock
Keytruda may have a long road ahead for its next approval after a stop at ODAC. • Source: photo illustration/Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers